Christopher Jackson has substantial experience in products liability and Medicaid fraud litigation, patent litigation, complex commercial litigation, and international arbitration. He has also done extensive work in employment and anti-discrimination litigation, including Cohen & Gresser’s service as the court-appointed Monitor overseeing the City of New York’s implementation of court-ordered reforms in the employment practices of the FDNY.
Chris has also handled trademark disputes and false advertising litigation as well as privacy law compliance in the context of cross-border litigation. Prior to joining the firm, he practiced at Patterson Belknap Webb & Tyler LLP.
Chris is a graduate of Columbia Law School, where he was a James Kent scholar and a Harlan Fiske Stone Scholar. He formerly served as Law Clerk to the Honorable Dickinson R. Debevoise of the U.S. District Court for the District of New Jersey. Prior to attending law school, Chris received his M.A. in English and his B.A., summa cum laude, from Columbia University. He is also a former world ranked professional squash player and is proficient in French.
Christopher Jackson has substantial experience in products liability and Medicaid fraud litigation, patent litigation, complex commercial litigation, and international arbitration. He has also done…
Columbia Law School (J.D. 2000); Columbia University (M.A. 1985; B.A., summa cum laude, 1981)
New York State; New Jersey State; U.S. District Courts for the Southern and Eastern Districts of New York; U.S. District Court for the District of New Jersey
Activities and Affiliations
Member, New York City Bar Association
Former Member, Law360 Editorial Advisory Board (for Life Sciences Coverage)
- Mark S Cohen, Partner: White Collar Advisory Board
- Robert J Gavigan, Partner: Mergers & Acquisitions Advisory Board
- Bonnie J Roe, Partner: Private Equity Advisory Board
- Daniel H Tabak, Partner: Legal Ethics Advisory Board
- Christopher M P Jackson, Counsel: Life Sciences Advisory Board
The article provides an analysis of recent remarks by Assistant Attorney General Stuart Delery, in which the AAG described the government’s approach to enforcement actions targeting off-label promotion of drugs and devices. Considering the AAG’s remarks along with recent FDA draft guidance on the distribution of scientific literature, the article focuses on the effect that First Amendment concerns, intensified by recent case law developments, may have had on the way in which the government investigates cases, evaluates evidence, and develops and presents its theories of liability in off-label cases.
- Litigation & Arbitration
- Intellectual Property & Technology